Please login to the form below

Not currently logged in
Email:
Password:

Profil Institute appoints former Amylin CEO

Dan Bradbury joins board of diabetes company

The Profil Institute for Clinical Research has appointed Dan Bradbury to its board of directors.

Bradbury is an experienced figure in the life science industry, serving as CEO of Amylin from 2007 to 2012 until its acquisition by Bristol-Myers Squibb.

He is currently a managing member of the life sciences consultancy firm BioBrit.

Dr Marcus Hompesch, CEO of diabetes-focused Profil Institute said: “Dan Bradbury is a highly regarded and prominent leader in the global pharmaceutical industry.”

He added: “With Mr Bradbury's considerable experience in driving strategic growth, I am certain that he will bring tremendous insight and guidance to help further shape the company's strategic course.”

7th November 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics